Cibus Q1 net loss $49.4M; cash $23.6M into Q3; evaluates strategic alternatives

Cibus, Inc.

2025-Q1 EPS reported -$1.34 revenue$1,034,000

Net loss of $49.4M ($1.34 per share) vs $27.0M a year ago; includes $21.0M non-cash goodwill impairment.
Cash and cash equivalents $23.6M as of March 31, 2025; expects to fund operations into Q3 2025 without new financing.
Board and financial advisor evaluating a full range of strategic alternatives to maximize shareholder value.
Regulatory wins: Ecuador deemed HT1/HT3 rice traits equivalent to conventional; USDA-APHIS classified two canola disease resistance traits as not regulated.
Rice trait commercialization on track for 2027; customer germplasm integration underway in North and South America.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.